Skip Navigation


Carcinogenesis Advance Access originally published online on January 14, 2008
Carcinogenesis 2008 29(6):1228-1234; doi:10.1093/carcin/bgn016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/6/1228    most recent
bgn016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rogozin, E. A.
Right arrow Articles by Dong, Z.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogozin, E. A.
Right arrow Articles by Dong, Z.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Inhibitory effects of caffeine analogues on neoplastic transformation: structure–activity relationship

Evgeny A. Rogozin1,{dagger}, Ki Won Lee1,2,{dagger}, Nam Joo Kang1, Haoyu Yu3, Masaaki Nomura4, Ken-Ichi Miyamoto5, Allan H. Conney6, Ann M. Bode1 and Zigang Dong1,*

1 Hormel Institute, University of Minnesota, Austin, MN 55912, USA
2 Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, South Korea
3 Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA
4 Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa 920-1181, Japan
5 Department of Hospital Pharmacy, School of Medicine, Kanazawa University, Kanazawa 920-8641, Japan
6 Department of Chemical Biology, College of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08855-0789, USA

* To whom correspondence should be addressed. Tel: +507 437 9600; Fax: +507 437 9606; Email: zgdong{at}hi.umn.edu

Some xanthine analogues, including 1,3,7-trimethylxanthine (caffeine) and 1,3-dimethylxanthine (theophylline), have been shown to exert anticancer activities in both cell culture and animal models. The present study focused on the relationship of structure and activity of 50 different caffeine analogues in preventing epidermal growth factor (EGF)-induced malignant transformation of mouse epidermal JB6 promotion-sensitive (P+) Cl41 (JB6 P+) cells. Results indicated that the inhibition of cell transformation by the 1,3,7-trialkylxanthines depends on the number of carbons at the alkyl groups R1 and R3, but not R7. Notably, 1-ethyl-3-hexylxanthine (xanthine 70) was the most effective compound for inhibiting EGF-induced neoplastic transformation among the 50 xanthine analogues tested. The 50% inhibition of cell transformation (ICT50) value for xanthine 70 was 48- or 75-fold less than the ICT50 value of caffeine or theophylline, respectively. Further study revealed that xanthine 70 (5–40 µM) dose dependently inhibited EGF-induced transactivation of activator protein 1 (AP-1), whereas theophylline or caffeine (up to 500 µM) had no effect on AP-1 activity. In addition, xanthine 70 (10 µM) inhibited 12-O-tetradecanoylphorbol-13-acetate- or H-Ras-induced neoplastic transformation in JB6 P+ cells by 78.2 or 62.0%, respectively. Collectively, these results indicated that the number of carbons at R1 and R3 is important for the antitumor-promoting activity of the trialkylxanthines and xanthine 70 might be a promising anticancer agent.

Abbreviations: AP-1, activator protein 1; EGF, epidermal growth factor; FBS, fetal bovine serum; ICT50, 50% inhibition of cell transformation; MEM, minimum essential medium; P+, promotion sensitive; TPA, 12-O-tetradecanoylphorbol-13-acetate


{dagger} These authors contributed equally to this work.

Received June 28, 2007; revised January 4, 2008; accepted January 7, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.